P53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Murata, Asuka ^a   Baba, Yoshifumi ^a   Watanabe, Masayuki ^a   Shigaki, Hironobu ^a   Miyake, Keisuke ^a   Karashima, Ryuichi ^a   Imamura, Yu ^a   Ida, Satoshi ^a   Ishimoto, Takatsugu ^a   Iwagami, Shiro ^a   Sakamoto, Yasuo ^a   Miyamoto, Yuji ^a   Yoshida, Naoya ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Esophageal squamous cell carcinoma; IHC; p53; Prognosis

Indexed keywords

PROTEIN P53;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; GENETICS; METHODOLOGY; MORTALITY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL;

AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883619245     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0728-z     Document Type: Article

References (57)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-52. (Pubitemid 37485141)
2. Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46-50.
3. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-7.
4. Gertler R, Stein HJ, Langer R, Nettelmann M, Schuster T, Hoefler H, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 2011;253:689-98.
5. Hong L, Han Y, Zhang H, Li M, Gong T, Sun L, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010;251:1056-63.
6. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, et al. Genetic variations in the PI3 K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009;27:857-71.
7. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749-58.
8. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413-31.
9. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-78. (Pubitemid 24289415)
10. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?-Revisited! J Pathol. 1994;172:1-4. (Pubitemid 24074994)
11. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res. 1992;52:6092-7.
12. Qiao GB, Han CL, Jiang RC, Sun CS, Wang Y, Wang YJ. Overexpression of P53 and its risk factors in esophageal cancer in urban areas of Xi'an. World J Gastroenterol. 1998;4:57-60. (Pubitemid 128620109)
13. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992;166:329-30.
14. Okumura H, Kita Y, Yokomakura N, Uchikado Y, Setoyama T, Sakurai H, et al. Nuclear expression of 14-3-3 sigma is related to prognosis in patients with esophageal squamous cell carcinoma. Anticancer Res. 2010;30:5175-9.
15. Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H, et al. No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol. 1999;72:94-8. (Pubitemid 29504128)
16. Sarbia M, Borchard F, Gabbert HE, Porschen R, Horstmann O, Willers R. P53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer. 1994;74:2218-23.
17. Baba Y, Watanabe M, Shigaki H, Iwagami S, Ishimoto T, Iwatsuki M, et al. Negative lymph-node count is associated with survival in patients with resected esophageal squamous cell carcinoma. Surgery. 2013;153:234-41.
18. Ozawa S, Baba S, Fujishiro M, Matsubara H, Numasaki H, Oyama T, et al. Comprehensive Registry of Esophageal Cancer in Japan. Esophagus. 2012;9:75-98.
19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-4. (Pubitemid 41258223)
20. Lam KY, Loke SL, Chen WZ, Cheung KN, Ma L. Expression of p53 in oesophageal squamous cell carcinoma in Hong Kong Chinese. Eur J Surg Oncol. 1995;21:242-7.
21. Yokoyama A, Tanaka Y, Yokoyama T, Mizukami T, Matsui T, Maruyama K, et al. p53 protein accumulation, iodine-unstained lesions, and alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 genotypes in Japanese alcoholic men with esophageal dysplasia. Cancer Lett. 2011;308:112-7.
22. Goan YG, Chang HC, Hsu HK, Chou YP, Cheng JT. Risk of p53 gene mutation in esophageal squamous cell carcinoma and habit of betel quid chewing in Taiwanese. Cancer Sci. 2005;96:758-65. (Pubitemid 43019826)
23. Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Tajima K, et al. Expression of p53 protein related to smoking and alcoholic beverage drinking habits in patients with esophageal cancers. Cancer Lett. 2001;167:65-72. (Pubitemid 32373270)
24. Mizobuchi S, Furihata M, Sonobe H, Ohtsuki Y, Ishikawa T, Murakami H, et al. Association between p53 immunostaining and cigarette smoking in squamous cell carcinoma of the esophagus. Jpn J Clin Oncol. 2000;30:423-8.
25. Taghavi N, Biramijamal F, Sotoudeh M, Moaven O, Khademi H, Abbaszadegan MR, et al. Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol. 2010;16:4958-67.
26. Tanaka F, Yamamoto K, Suzuki S, Inoue H, Tsurumaru M, Kajiyama Y, et al. Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut. 2010;59:1457-64.
27. Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010;59:39-48.
28. Morita M, Kumashiro R, Kubo N, Nakashima Y, Yoshida R, Yoshinaga K, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol. 2010;15:126-34.
29. Yokoyama A, Kumagai Y, Yokoyama T, Omori T, Kato H, Igaki H, et al. Health risk appraisal models for mass screening for esophageal and pharyngeal cancer: an endoscopic follow-up study of cancer-free Japanese men. Cancer Epidemiol Biomarkers Prev. 2009;18:651-5.
30. Yokoyama A, Omori T, Yokoyama T, Sato Y, Mizukami T, Matsushita S, et al. Risk of squamous cell carcinoma of the upper aerodigestive tract in cancer-free alcoholic Japanese men: an endoscopic follow-up study. Cancer Epidemiol Biomarkers Prev. 2006;15:2209-15. (Pubitemid 44883052)
31. Wang LD, Zhou Q, Hong JY, Qiu SL, Yang CS. p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan China. Cancer. 1996;77:1244-9. (Pubitemid 26102320)
32. Shigaki H, Baba Y, Watanabe M, Iwagami S, Miyake K, Ishimoto T, et al. LINE-1 hypomethylation in noncancerous esophageal mucosae is associated with smoking history. Ann Surg Oncol. 2012;19:4238-43.
33. Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, Kaminishi M, et al. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer. 2009;115:3412-26.
34. Lam KY, Law S, Tin L, Tung PH, Wong J. The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients. Am J Gastroenterol. 1999;94:2060-8. (Pubitemid 29374532)
35. Yen CC, Tsao YP, Chen PC, Wu YC, Liu JH, Pan CC, et al. PML protein as a prognostic molecular marker for patients with esophageal squamous cell carcinomas receiving primary surgery. J Surg Oncol. 2011;103:761-7.
36. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer. 1994;74:2218-23.
37. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, et al. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virchows Arch A Pathol Anat Histopathol. 1993;422:271-6. (Pubitemid 23169371)
38. Wang LD, Shi ST, Zhou Q, Goldstein S, Hong JY, Shao P, et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer. 1994;59:514-9. (Pubitemid 24357277)
39. Sarbia M, Ott N, Puhringer-Oppermann F, Brucher BL. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer. 2007;97:1404-8. (Pubitemid 350114789)
40. Okamoto H, Fujishima F, Nakamura Y, Zuguchi M, Ozawa Y, Takahashi Y, et al. Significance of CD133 expression in esophageal squamous cell carcinoma. World J Surg Oncol. 2013;11:51.
41. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Clinicopathologic significance of the expression of mutated p53 protein and the proliferative activity of cancer cells in patients with esophageal squamous cell carcinoma. J Am Coll Surg. 1997;185:398-403. (Pubitemid 27419198)
42. Chanvitan A, Nekarda H, Casson AG. Prognostic value of DNA index, S-phase fraction and p53 protein accumulation after surgical resection of esophageal squamous-cell carcinomas in Thailand. Int J Cancer. 1995;63:381-6.
43. Furihata M, Ohtsuki Y, Ogoshi S, Takahashi A, Tamiya T, Ogata T. Prognostic significance of human papillomavirus genomes (type-16, -18) and aberrant expression of p53 protein in human esophageal cancer. Int J Cancer. 1993;54:226-30. (Pubitemid 23154886)
44. Nakamura T, Ide H, Eguchi R, Hayashi K, Hanyu F, Nagasako K, et al. Expression of p53 protein related to human papillomavirus and DNA ploidy in superficial esophageal carcinoma. Surg Today. 1995;25:591-7.
45. Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol. 1998;51:71-9. (Pubitemid 28261244)
46. Monges GM, Seitz JF, Giovannini MF, Gouvernet JM, Torrente MA, Hassoun JA. Prognostic value of p53 protein expression in squamous cell carcinoma of the esophagus. Cancer Detect Prev. 1996;20:63-7. (Pubitemid 2627097)
47. Yamamoto Y, Yamai H, Seike J, Yoshida T, Takechi H, Furukita Y, et al. Prognosis of Esophageal Squamous Cell Carcinoma in Patients Positive for Human Epidermal Growth Factor Receptor Family Can Be Improved by Initial Chemotherapy with Docetaxel, Fluorouracil, and Cisplatin. Ann Surg Oncol. 2011;19:757-65.
48. Rosa AR, Schirmer CC, Gurski RR, Meurer L, Edelweiss MI, Kruel CD. Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis Esophagus. 2003;16:112-8. (Pubitemid 36992384)
49. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer. 1997;79:425-32.
50. Goukon Y, Sasano H, Nishihira T, Nagura H, Mori S. p53 overexpression in human esophageal carcinoma: a correlation with tumor DNA ploidy and two parameter flow cytometric study. Anticancer Res. 1994;14:1305-12. (Pubitemid 24264179)
51. Inada S, Koto T, Futami K, Arima S, Iwashita A. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999;29:493-503. (Pubitemid 29313958)
52. Hsia JY, Chen CY, Hsu CP, Shai SE, Yang SS, Chuang CY, et al. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma. 2001;48:483-8. (Pubitemid 34132564)
53. Uchino S, Saito T, Inomata M, Osawa N, Chikuba K, Etoh K, et al. Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol. 1996;26:287-92. (Pubitemid 126470685)
54. Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C, Matthews HR. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg. 1994;81:1623-6. (Pubitemid 24349937)
55. Chyczewski L, Kozlowski M, Niklinski J, Szyszko J, Laudanski J, Niklinska W. p53 protein expression in resected invasive esophageal cancer. Neoplasma. 1999;46:150-5. (Pubitemid 29398313)
56. Patel DD, Bhatavdekar JM, Chikhlikar PR, Patel YV, Shah NG, Ghosh N, et al. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach. J Surg Oncol. 1997;65:111-6. (Pubitemid 27283921)
57. Pomp J, Davelaar J, Blom J, van Krimpen C, Zwinderman A, Quint W, et al. Radiotherapy for oesophagus carcinoma: the impact of p53 on treatment outcome. Radiother Oncol. 1998;46:179-84. (Pubitemid 28109176)